Scholarlink

Background <p>Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI)  ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC.</p> Methods <p>Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS).</p> Results <p>Data from eligible patients treated between 2005 and 2023 were retrospectively collected. 201 (50%) patients received ADT monotherapy, while 124 (31%) and 76 (19%) received ADT+docetaxel and ADT + ARPI, respectively. 365 (91%) patients underwent first-line treatment for mCRPC—majority of the ADT monotherapy received ARPI (38%) or docetaxel (34%), whereas 69% of the ADT+docetaxel received ARPI and 62% of the ADT + ARPI received docetaxel. In the group of patients treated with ADT the median PFS was 6.8 months while the median OS was 26.4. In the group of patients treated with combination therapy the median PFS and OS was 4.9 and 18.6 months for patients who received docetaxel and 5.6 and 19.5 months for patients who received ARPI, respectively. Neither the first-line mCRPC treatment nor the genetic profiles were associated with survival outcomes.</p> Conclusions <p>The results of our study suggest that patients with EP mHSPC are characterized by poor outcomes regardless of the type of treatment received at progression. The optimal first-line mCRPC therapy to use in these patients remains a crucial unmet clinical need.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

  • 期刊论文

  • 发表日期：

    2026年5月29日

查看全文
  • Fabio Turco,
  • Silke Gillessen,
  • Giuseppe Salfi,
  • Iris S. H. Kloots,
  • Peter H. J. Slootbeek,
  • Niven Mehra,
  • Matthew Labriola,
  • Daniel J. George,
  • Amanda Broderick,
  • Anna Patrikidou,
  • Hortense Patry,
  • Consuelo Buttigliero,
  • Veronica Crespi,
  • Hirotsugu Uemura,
  • Kazutoshi Fujita,
  • Takanobu Utsumi,
  • Hiroyoshi Suzuki,
  • Daniele Raggi,
  • Umberto Basso,
  • Rafael Morales-Barrera,
  • David Marmolejo Castaneda,
  • Cora N. Sternberg,
  • Daniela Guevara,
  • Orazio Caffo,
  • Giuseppe Procopio,
  • Andrea Zivi,
  • Sara Merler,
  • Mariella Sorarù,
  • Daniel E. Spratt,
  • Pedro C. Barata,
  • Carlo Messina,
  • Yüksel ürün,
  • Hatice Bolek,
  • Ignacio Duràn,
  • Juan Diego Cacho Lavin,
  • Nieves Martínez Chanzá,
  • Lisa G. Horvath,
  • Rhiannon Mellor,
  • Levent Türkeri,
  • Merve Bengisu Soykök,
  • Sabrina Rossetti,
  • Richard Cathomas,
  • Giuseppe Luigi Banna,
  • Vincenza Conteduca,
  • Margaret Ottaviano,
  • Laura Marandino,
  • Hui-Ming Lin,
  • Luigi Tortola,
  • Ricardo Pereira Mestre,
  • Martino Pedrani

摘要

Background

Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI)  ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC.

Methods

Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS).

Results

Data from eligible patients treated between 2005 and 2023 were retrospectively collected. 201 (50%) patients received ADT monotherapy, while 124 (31%) and 76 (19%) received ADT+docetaxel and ADT + ARPI, respectively. 365 (91%) patients underwent first-line treatment for mCRPC—majority of the ADT monotherapy received ARPI (38%) or docetaxel (34%), whereas 69% of the ADT+docetaxel received ARPI and 62% of the ADT + ARPI received docetaxel. In the group of patients treated with ADT the median PFS was 6.8 months while the median OS was 26.4. In the group of patients treated with combination therapy the median PFS and OS was 4.9 and 18.6 months for patients who received docetaxel and 5.6 and 19.5 months for patients who received ARPI, respectively. Neither the first-line mCRPC treatment nor the genetic profiles were associated with survival outcomes.

Conclusions

The results of our study suggest that patients with EP mHSPC are characterized by poor outcomes regardless of the type of treatment received at progression. The optimal first-line mCRPC therapy to use in these patients remains a crucial unmet clinical need.